**Core tip:** We herewith present a case report of a patient with advanced pancreatic cancer with a survival time of 63 mo despite 2 times of relapse und continuous treatment with *Viscum album* extracts. The patient preserved a good quality of live, regained his weight after weight loss during chemotherapy and is currently working full-time in his job.

INTRODUCTION
============

Pancreatic cancer (PC) is a common malignancy (incidence 12.6/100.000 in the United States\[[@B1]\]), with a dismal prognosis (5-year survival of 2%\[[@B2]\]), especially in cases of locally advanced disease (median survival of 8-12 mo\[[@B3]\]). Intraductal papillary mucinous neoplasm (IPMN)-associated invasive adenocarcinoma of the pancreas is a histologic subtype of PC that has to be kept distinct from mucinous cystic neoplasms of the pancreas\[[@B4]\]; IPMN-associated invasive adenocarcinoma shows a better prognosis due to earlier onset of clinical symptoms compared to pancreatic ductal adenocarcinoma (PDA). However, prognosis of IPMN-associated and standard PDA are equally poor when compared by stage\[[@B5]\]. In all PC patients in which R0-resection seems feasible, surgery is recommended. R0-resected patients show a strong survival benefit compared to R1-resected patients\[[@B6]\]. Type of chemotherapy regimen - as primary or adjuvant treatment - is chosen according to tumor stage and performance status\[[@B7]\]. Radiofrequency ablation (RFA) is increasingly used in advanced PC (aPC); the procedure is safe, but comparative randomized trials on effectiveness are lacking\[[@B8]-[@B10]\].

*Viscum album* (European mistletoe, *Viscum album L*.) is a hemiparasitic shrub, growing on different host trees (oak, apple, pine and others). Aqueous *Viscum album* extracts (VAE) show a variety of antineoplastic properties including cytotoxic effects, apoptosis induction, immune stimulation, down-regulation of cancer genes (*e.g*., transforming growth factor β and matrix-metalloproteinases), reduction of cell migration, and reduction of tumor angiogenesis\[[@B11]-[@B14]\]. Active compounds of VAE are especially mistletoe lectins and viscotoxins, but also oligo- and polysaccharides, flavonoids, and triterpene acids\[[@B14]\]. Injectable forms of VAE preparations (typically for subcutaneous use, or - as off-label use - for intralesional or intravenous application) are commercially available, and are used as supportive cancer therapy \[[@B15]\]. VAE show a common range of local reactions such as erythema at the injection site and general reactions like fever and flu-like symptoms. Rarely, pseudo allergic reactions can occur. VAE are safe, even when used in higher dosages \[[@B16]\].

CASE PRESENTATION
=================

Chief complaints
----------------

A 59-year-old architect developed epigastric pain. He had a body mass index (BMI) of 30 (body weight of 92 kg, height of 175 cm) and was a nonsmoker.

History of present illness
--------------------------

Nothing to declare.

History of past illness
-----------------------

The patient had a history of bronchial asthma and suffered from gastroesophageal reflux disease, which was treated with esomeprazole.

Personal and family history
---------------------------

His father had died from metastatic colon cancer.

Laboratory examinations
-----------------------

CA-19-9 was elevated to 58.5 U/mL.

Imaging examinations
--------------------

A cystic lesion of the pancreas of 45-mm diameter was seen in ultrasound and confirmed by computed tomography (CT) scan. In a follow-up magnetic resonance imaging (MRI), about one year after initial symptoms, multiple lesions were seen in the corpus and the tail of the pancreas (Figure [1A](#F1){ref-type="fig"} and B). A splenopancreatectomy was performed, and a tumor of 7 cm × 5 cm × 3.5 cm of the pancreatic tail was excised. Histologic investigation showed a poorly demarcated IPMN-associated hypermuzinous invasive adenocarcinoma with invasion of the lymph vessels, perineural invasion, and positive nodes (2/27); the tumor was 1 mm in the ventral resection margin, and the dorsal margin showed tumor parts (Figure [2](#F2){ref-type="fig"}). The tumor was classified as pT3 N1 M0 R1.

![Magnetic resonance imaging images of the tumor lesions. A and B: primary tumor lesion 2 mo before the initial diagnosis: cystic lesion at the location between body and tail of the pancreas with a size of 43 mm × 38 mm × 30 mm; dilatation of the pancreatic duct of 13 mm (A: T2 axial, B: T2 coronal); C and D: Relapsed hepatic lesion in segment VIII in month 20 after initial diagnosis (C: T1 axial, D: T1 coronal).](WJG-25-1524-g001){#F1}

![Patient's tumor, haematoxylin and eosin stain. A: × 100; B: × 200; C :( × 400) invasive mucinous adenocarcinoma; D and E: (× 100) perineural invasion.](WJG-25-1524-g002){#F2}

FINAL DIAGNOSIS
===============

A patient with aPC.

TREATMENT
=========

The patient was treated with radiation of the tumor bed (59.4 Gy) and capecitabine and oxaliplatin followed by gemcitabine and 8 cycles of FOLFIRINOX (folinic acid 390 mg, fluorouracil 4700 mg, irinotecan 340 mg, oxaliplatin 150 mg).

OUTCOME AND FOLLOW-UP
=====================

About 7 mo after surgery, a liver metastasis 2 cm in diameter in segment VIII was detected, and therefore treatment with FOLFIRINOX was started. Four months after detection of the metastasis the patient opted for additional continuous treatment with VAE (Iscador Qu 10 mg, 3 injections per week). Another month later, the metastasis was still unchanged despite chemotherapy and therefore treated with RFA. Eight months later, the hepatic lesion recurred within the scar tissue of the first metastasis, showing a lesion about 2 cm in diameter (Figure [1C](#F1){ref-type="fig"} and D). It was again treated by RFA and by a dose increase of VAE (Figure [3](#F3){ref-type="fig"}). The lesion regressed again and the patient stayed recurrence-free for the next 39 mo (as of the writing of this case report; for details of the disease and treatment course, see Figure [3](#F3){ref-type="fig"}).

![Timeline of the patient with advanced pancreatic cancer. Gy: Radiotherapy in Gray; CAPOX: Capecitabine + oxaliplatin; GEMC: Gemcitabine; FOLIFIRINOX: Leucovorin + fluorouracil + irinotecan + oxaliplatin.](WJG-25-1524-g003){#F3}

DISCUSSION
==========

We present a case of a 59-year-old patient with an aPC who underwent resection but showed positive margins (R1), with two relapses (liver metastases) after radiochemotherapy and RFA of metastases. The patient continuously received an adjunct treatment with VAE in increasing doses beginning shortly after detection of the liver metastasis and continuing until present. He showed prolonged survival and good health 63 mo after initial diagnosis. The patient had an advanced primary tumor, perineural invasion, lymph vascular invasion, node involvement, and positive resection margins - all of which are independent negative prognostic factors\[[@B17]\]. In this patient, surgical excision was possible - a circumstance associated with an improved prognosis. However, median survival of PC patients who have undergone surgical excision, regardless of stage or other prognostic factors, is 19 mo (interquartile range, 10-42 mo)\[[@B18]\].

VAE was repeatedly investigated in PC and showed cytotoxic effects in cell lines and animal studies (PA-TU-8902, PAXF 736, PAXF 546)\[[@B19]-[@B21]\]. Tröger et al\[[@B22]\] found a survival benefit for aPC patients solely treated with VAE in a randomized controlled trial on overall survival. Similar results were seen by Axtner et al\[[@B23]\] in an integrative oncology registry. In a phase 1 study of VAE and Gemcitabine in patients with advanced solid tumors (including PC) it could be shown, that VAE did not affect the pharmacokinetics of Gemcitabine\[[@B24]\]. VAE in PC is currently further investigated in clinical trials (NCT02948309).

RFA acts through direct thermal cell damage but shows additional immune stimulatory properties as tumor antigens and a variety of cytokines are released from the treated tumor tissue; increased numbers of tumor-specific T cells have been detected in RFA-treated patients\[[@B10]\]. Combination therapy of RFA with different immune-stimulatory agents showed promising results\[[@B25],[@B26]\]. The combination of VAE with radiation - which, like RFA, leads to cell damage and to a release of antigens - proved to be more effective than radiation alone in animal studies\[[@B27],[@B28]\]. VAE shows several immune-stimulating properties like proliferation induction and increase of antigen presentation of dendritic cells, proliferation of CD4^+^ T cells, increase of natural killer cell-mediated cytotoxicity, and release of cytokines\[[@B14]\].

CONCLUSION
==========

We presume that VAE acted synergistically with RFA, leading to tumor control. Reports of combined treatment with RFA and VAE should be collected to determine whether further investigations in this area are worthwhile.
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